Profile
ACOR ZTS TAK HLN TEVA ITCI
Company Name Acorda Therapeutics, Inc. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Intra-Cellular Therapies, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $821.03K $73.61B $47.68B $46.95B $17.60B $13.95B
Employees 0.10K 13.80K 49.28K 25.41K 33.89K 0.86K
CEO Dr. Ron Cohen M.D. Ms. Kristin C. Peck Mr. Christophe Weber Mr. Brian James McNamara Mr. Richard D. Francis Dr. Sharon Mates Ph.D.
Ratings
ACOR ZTS TAK HLN TEVA ITCI
Quant Rating Score 3 3 3 2 1 1
Quant Rating Neutral Neutral Neutral Sell Strong Sell Strong Sell
Trading
ACOR ZTS TAK HLN TEVA ITCI
Last Close $0.661 $164.39 $14.9 $10.39 $16.1 $131.24
High 52 $13.5 $196.48 $15.17 $10.69 $22.77 $131.28
Low 52 $0.66 $145.54 $12.6 $8.01 $12.78 $64.37
Price vs. 52 Week High -95.1 % -16.33 % -1.78 % -2.81 % -29.29 % -0.03 %
Price vs. 52 Week Low 0.15 % 12.95 % 18.25 % 29.71 % 25.98 % 103.88 %
Total Return
ACOR ZTS TAK HLN TEVA ITCI
1 Month Return 0 % -5.46 % 12.37 % 5.38 % -1.47 % 2.56 %
3 Month Return 0 % -7.74 % 11.03 % 6.45 % -2.42 % 58.06 %
6 Month Return 0 % -13.8 % 0.54 % 0.1 % -10.61 % 74.47 %
9 Month Return 0 % -6.52 % 11.69 % 24.88 % -6.5 % 92.43 %
YTD Return 0 % 0.9 % 12.54 % 8.91 % -26.95 % 57.14 %
1 Year Return -94.78 % -9.35 % 3.69 % 19.98 % 19.35 % 103.88 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ACOR ZTS TAK HLN TEVA ITCI
Dividend Yield Percentage (TTM) - 1.09 % 4.28 % 0.02 % - -
Dividend Paid and Capex Coverage Ration (TTM) -102.84 % 2.05 % 1.76 % - 2.5 % -227.26 %
Dividend Per Share (TTM) - 1.8 % 192 % 0.06 % - -
Payout Ratio (TTM) - 31.62 % 145.09 % - - -
Growth
ACOR ZTS TAK HLN TEVA ITCI
Asset Growth -70.24 % -2.18 % -9.55 % 87.69 %
Gross Profit Growth -18.87 % 5.84 % 5.47 % 44.88 %
Revenue Growth -0.79 % 4.09 % 4.4 % 46.62 %
Revenue 3 Year -74.97 % 13.9 % 1.52 % 556.51 %
Revenue 5 Year -92.13 % 32.87 % -5.5 % 600974.32 %
Revenue 10 Year -90.22 % 32.87 % -38.45 % 32663.23 %
EBIT Growth 44.66 % 9.37 % -169.98 % 26.77 %
Net Income Growth -283.6 % -1.04 % -193.2 % 46.54 %
Net Income 3 Yeari Growth Per Share 17.38 % -8.67 % -482.97 % 79.29 %
Net Income 5 Yeari Growth Per Share -336.79 % 59.66 % -58.26 % 72.95 %
Net Income 10 Yeari Growth Per Share -530.12 % 59.66 % -140.46 % 32.41 %
Operating Income Growth 44.66 % 9.37 % -169.98 % 26.77 %
Operating Cash Flow Growth (CFG) 33.17 % 1.79 % -8.85 % 41.08 %
Operating 3 Year CFG 92.54 % 48.8 % 52.26 % 77.79 %
Operating 5 Year CFG -102.93 % 166.36 % 123.59 % 69.4 %
Operating 10 Year CFG -109.96 % 166.36 % -81.66 % 10.87 %
EPS Growth -204.32 % - -190 % 50.68 %
EPS Diluted Growth -204.32 % - -190 % 50.68 %
Book Value Per Share -233.85 % 1.35 % -30.36 % 80.54 %
Share Holder 3 Year Equity Growth Per Share -121.6 % -36.6 % -49 % 116.52 %
Share Holder 5 Year Equity Growth Per Share -108.14 % -39.41 % -62.86 % 215.14 %
Share Holder 10 Year Equity Growth Per Share -110.03 % -39.41 % -82.6 % 164.65 %
Dividend Per Share Growth - -85.58 % - -
Dividend 3 Year Growth Per Share - -83.69 % - -
Dividend 5 Year Growth Per Share -100 % -66.42 % -100 % -
Dividend 10 Year Growth Per Share - -66.42 % -100 % -
Debt Growth 10.4 % -9.43 % -10.29 % 0.25 %
Free Cash Flow Growth 32.35 % 1.67 % -11.05 % 40.95 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2024 31 Dec 2024
Profitability
ACOR ZTS TAK HLN TEVA ITCI
Gross Profit Margin TTM 79.73 % 69.85 % 54.74 % 61.06 % 48.74 % 91.63 %
Return on Assets TTM -322.92 % 17.46 % 1.38 % 3.62 % -4.17 % -5.46 %
Return on Equity TTM 485.8 % 49.65 % 2.83 % 7.27 % -26.15 % -7.4 %
Return on Capital Employed TTM 17.07 % 24.27 % 3.62 % 7.66 % -1.14 % -10.05 %
Net Income Per EBT TTM 86.53 % 79.35 % 89.75 % 67.34 % 127.75 % 100.64 %
EBT Per Ebit TTM 1252.94 % 119.26 % 49.18 % 84.34 % 423.43 % 63.57 %
EBIT Per Revenue TTM -21.01 % 28.38 % 10.3 % 18.92 % -1.83 % -17.15 %
Cash Flow To Debt Ratio TTM -13.86 % 43.79 % 22.2 % - 6.9 % -430.93 %
Receivables Turnover TTM 12.59 7.03 6.23 5.26 5.41 4.09
Payables Turnover TTM 2.36 6.45 4.5 1.22 3.85 2.18
Inventory Turnover TTM 1.66 1.21 1.66 2.99 2.82 2.17
Fixed Asset Turnover TTM 1982.58 % 256.4 % 226.93 % 603.65 % 334.34 % 4569.25 %
Asset Turnover TTM 141.79 % 65.01 % 30.31 % 33.66 % 42.07 % 49.79 %
Operating Cash Flow Per Share TTM -21.86 6.5 678.77 - 1.1 -0.71
Free Cash Flow Per Share TTM -22.07 5.06 484.07 - 0.66 -0.71
Cash Per Share TTM 753.95 % 437.03 % 33271.95 % 5.75 % 291.26 % 970.67 %
Operating Cash Flow Sales Ratio TTM -23.47 % 31.9 % 23.47 % - 7.54 % -10.75 %
Free Cash Flow Operating Cash Flow Ratio TTM 100.97 % 77.82 % 71.32 % - 60.06 % 100.44 %
Cash Flow Coverage Ratios TTM -13.86 % 43.79 % 22.2 % - 6.9 % -430.93 %
Price To Free Cash Flows Ratio TTM -0.03 32.03 9.28 - 23.05 -189.86
Price To Operating Cash Flows Ratio TTM -0.03 25.28 6.61 - 13.69 -184.96
Price Cash Flow Ratio TTM -0.03 25.28 6.61 - 13.69 -184.96
Income Statement (TTM)
ACOR ZTS TAK HLN TEVA ITCI
Revenue $0.12B $9.26B $4263.76B $11.3B $16.54B $0.68B
Gross Profit $0.07B $6.54B $2832.26B $6.96B $8.06B $0.62B
Gross Profit Ratio 60.9% 70.62% 66.4% 61.59% 48.74% 91.63%
EBITDA $0.01B $3.86B $874.6B $2.35B $-0.3B $-0.12B
Net Income $-0.25B $2.49B $144.07B $1.05B $-1.64B $-0.07B
EPS Diluted -203.59 5.47 91.16 0.11 -1.45 -0.72
Balance Sheet (MRQ)
ACOR ZTS TAK HLN TEVA ITCI
Long Term Debt $0B $5.39B $5029.93B $8.8B $16.3B $0.01B
Total Liabilities $0.28B $9.47B $7834.79B $17.33B $33.61B $0.22B
Total Equity $-0.16B $4.77B $7274.01B $16.73B $5.72B $1.15B
Total Investments $0B $0B $445.7B $0.07B $0B $0.69B
Total Debt $0.19B $6.74B $4843.75B $9.46B $18.08B $0.02B
Total Assets $0.12B $14.24B $15108.79B $34.06B $39.33B $1.37B
Cash Flow Statement (TTM)
ACOR ZTS TAK HLN TEVA ITCI
Net Income $-0.25B $2.5B $144.07B $1.11B $-1.96B $-0.07B
Inventory $-0B $-0.04B $-115.74B $-0.13B $0.17B $-0.01B
Dividends Paid $0B $-0.79B $-287.19B $-0.39B $0B $0B
Operating Cash Flow $-0.01B $2.95B $716.34B $2.1B $1.25B $-0.07B
Capital Expenditure $-0B $-0.66B $-480.73B $-0.34B $-0.5B $-0B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.485
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.4702
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 11.44
ALVOW Alvotech 1.5
AMPH Amphastar Pharmaceuticals, Inc. 26.975
AMRX Amneal Pharmaceuticals, Inc. 8.85
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 62.645
AQST Aquestive Therapeutics, Inc. 2.65
ASRT Assertio Holdings, Inc. 0.765
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 7.855
AYTU Aytu BioPharma, Inc. 1.27
BDSI BioDelivery Sciences International, Inc. 5.59
ETFs With Exposure to ACOR
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 274.99
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00001 122.025
VXF Vanguard Extended Market Index Fund 0 173.535
VSTCX Vanguard Strategic Small-Cap Equity Fund Investor Shares 0 35.84
IEIH iShares Evolved U.S. Innovative Healthcare ETF 0 34.1348
VTSAX Vanguard Total Stock Market Index Fund 0 133.29
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 131.19
VITSX Vanguard Total Stock Market Index Fund 0 133.31
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 131.2
VEMPX Vanguard Extended Market Index InstlPlus 0 323.75
VSMPX Vanguard Total Stock Mkt Idx Instl Pls 0 250.07
Unlock